Ying-Ying Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ying-Ying Shen has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Yan-Jiang Wang
Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
6 shared publications Gui-Hua Zeng
Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
4 shared publications- Xian-Le Bu
Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
4 shared publications Xu Yi
Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
4 shared publicationsDong-Yu Fan
Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
3 shared publications- Fan Zeng
Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing, China
3 shared publications
Latest Publications
- Open Access
- 16 April 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-8
Trajectory of changes in myelin basic protein levels in cerebrospinal fluid during ageing and its association with biomarkers of Alzheimer’s disease
Myelin loss has been implicated in the development of Alzheimer’s disease (AD). We investigated the changes in myelin basic protein (MBP) levels in cerebrospinal fluid (CSF) in an ageing cohort comprising 116 cognitively normal and Aβ-negative controls aged 26 to 82 years, as well as in a clinical cohort. We found that CSF MBP levels was positively correlated with age in a nonlinear pattern over the lifetime of the ageing cohort and that CSF MBP continually increased until it began to decline around age of 51 years and rose again around age 62. CSF MBP levels were correlated with the Mini-Mental State Examination (MMSE) score and CSF phosphorylated tau-181 (p-tau181) and total tau (t-tau) levels but not the Aβ42/Aβ40 ratio. CSF MBP levels moderated age-related changes in cognitive function. In the clinical cohort, CSF MBP levels were higher in the CSF Aβ+ patients than in the CSF Aβ- participants, and CSF MBP levels were higher in the Aβ–PET+ patients than in the Aβ–PET- participants. CSF MBP levels were higher in apolipoprotein E ε4 allele (APOE-ε4) carriers than in APOE-ε4 noncarriers in the clinical cohort. Our study reveals the possible changes in CSF MBP levels during ageing and in AD patients, providing evidence that demyelination is involved in brain ageing and AD pathogenesis in humans.
- 16 April 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-8
Open AccessTrajectory of changes in myelin basic protein levels in cerebrospinal fluid during ageing and its association with biomarkers of Alzheimer’s disease
Myelin loss has been implicated in the development of Alzheimer’s disease (AD). We investigated the changes in myelin basic protein (MBP) levels in cerebrospinal fluid (CSF) in an ageing cohort comprising 116 cognitively normal and Aβ-negative controls aged 26 to 82 years, as well as in a clinical cohort. We found that CSF MBP levels was positively correlated with age in a nonlinear pattern over the lifetime of the ageing cohort and that CSF MBP continually increased until it began to decline around age of 51 years and rose again around age 62. CSF MBP levels were correlated with the Mini-Mental State Examination (MMSE) score and CSF phosphorylated tau-181 (p-tau181) and total tau (t-tau) levels but not the Aβ42/Aβ40 ratio. CSF MBP levels moderated age-related changes in cognitive function. In the clinical cohort, CSF MBP levels were higher in the CSF Aβ+ patients than in the CSF Aβ- participants, and CSF MBP levels were higher in the Aβ–PET+ patients than in the Aβ–PET- participants. CSF MBP levels were higher in apolipoprotein E ε4 allele (APOE-ε4) carriers than in APOE-ε4 noncarriers in the clinical cohort. Our study reveals the possible changes in CSF MBP levels during ageing and in AD patients, providing evidence that demyelination is involved in brain ageing and AD pathogenesis in humans.
- 16 February 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 104 (2) , 429-435
Clinical relevance of plasma ADAM-17 with cognition and neurodegeneration in Alzheimer's disease
Background: A disintegrin and metalloproteinase 17 (ADAM-17) has multiple pathophysiological functions in Alzheimer's disease (AD). However, the clinical relevance of ADAM-17 in AD is not clear yet. Objective: This study aims to investigate the levels of circulating ADAM-17 and their association with AD. Methods: This cross-sectional study recruited 40 normal cognition (NC) participants and 36 AD patients. Plasma ADAM-17 and biomarkers of neurodegeneration were determined. The association of plasma ADAM-17 with cognitive functions and biomarkers of neurodegeneration was analyzed. Results: Plasma ADAM-17 levels were elevated in AD patients in comparison with NC subjects. Plasma ADAM-17 was positively associated with Clinical Dementia Rating (CDR) scores, but negatively associated with the Mini-Mental State Examination scores and Montreal Cognitive Assessment scores. Plasma ADAM-17 levels were positively associated with the levels of Aβ 40 , Aβ 42 , and p-Tau181. Conclusions: These findings suggest a link between ADAM-17 and the pathogenesis of AD from a clinical perspective.
- 16 February 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 104 (2) , 429-435
Clinical relevance of plasma ADAM-17 with cognition and neurodegeneration in Alzheimer's disease
Background: A disintegrin and metalloproteinase 17 (ADAM-17) has multiple pathophysiological functions in Alzheimer's disease (AD). However, the clinical relevance of ADAM-17 in AD is not clear yet. Objective: This study aims to investigate the levels of circulating ADAM-17 and their association with AD. Methods: This cross-sectional study recruited 40 normal cognition (NC) participants and 36 AD patients. Plasma ADAM-17 and biomarkers of neurodegeneration were determined. The association of plasma ADAM-17 with cognitive functions and biomarkers of neurodegeneration was analyzed. Results: Plasma ADAM-17 levels were elevated in AD patients in comparison with NC subjects. Plasma ADAM-17 was positively associated with Clinical Dementia Rating (CDR) scores, but negatively associated with the Mini-Mental State Examination scores and Montreal Cognitive Assessment scores. Plasma ADAM-17 levels were positively associated with the levels of Aβ 40 , Aβ 42 , and p-Tau181. Conclusions: These findings suggest a link between ADAM-17 and the pathogenesis of AD from a clinical perspective.
- Open Access
- 16 June 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-9
Establishment of combined diagnostic models of Alzheimer’s disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS)
Cerebrospinal fluid (CSF) biomarkers are essential for the accurate diagnosis of Alzheimer’s disease (AD), yet their measurement levels vary widely across centers and regions, leaving no uniform cutoff values to date. Diagnostic cutoff values of CSF biomarkers for AD are lacking for the Chinese population. As a member of the Alzheimer’s Association Quality Control program for CSF biomarkers, we aimed to establish diagnostic models based on CSF biomarkers and risk factors for AD in a Chinese cohort. A total of 64 AD dementia patients and 105 age- and sex-matched cognitively normal (CN) controls from the Chongqing Ageing & Dementia Study cohort were included. CSF Aβ42, P-tau181, and T-tau levels were measured by ELISA. Combined biomarker models and integrative models with demographic characteristics were established by logistic regression. The cutoff values to distinguish AD from CN were 933 pg/mL for Aβ42, 48.7 pg/mL for P-tau181 and 313 pg/mL for T-tau. The AN model, including Aβ42 and T-tau, had a higher diagnostic accuracy of 89.9%. Integrating age and APOE ε4 status to AN model (the ANA’E model) increased the diagnostic accuracy to 90.5% and improved the model performance. This study established cutoff values of CSF biomarkers and optimal combined models for AD diagnosis in a Chinese cohort.
- 16 June 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-9
Open AccessEstablishment of combined diagnostic models of Alzheimer’s disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS)
Cerebrospinal fluid (CSF) biomarkers are essential for the accurate diagnosis of Alzheimer’s disease (AD), yet their measurement levels vary widely across centers and regions, leaving no uniform cutoff values to date. Diagnostic cutoff values of CSF biomarkers for AD are lacking for the Chinese population. As a member of the Alzheimer’s Association Quality Control program for CSF biomarkers, we aimed to establish diagnostic models based on CSF biomarkers and risk factors for AD in a Chinese cohort. A total of 64 AD dementia patients and 105 age- and sex-matched cognitively normal (CN) controls from the Chongqing Ageing & Dementia Study cohort were included. CSF Aβ42, P-tau181, and T-tau levels were measured by ELISA. Combined biomarker models and integrative models with demographic characteristics were established by logistic regression. The cutoff values to distinguish AD from CN were 933 pg/mL for Aβ42, 48.7 pg/mL for P-tau181 and 313 pg/mL for T-tau. The AN model, including Aβ42 and T-tau, had a higher diagnostic accuracy of 89.9%. Integrating age and APOE ε4 status to AN model (the ANA’E model) increased the diagnostic accuracy to 90.5% and improved the model performance. This study established cutoff values of CSF biomarkers and optimal combined models for AD diagnosis in a Chinese cohort.
- Open Access
- 10 May 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-6
Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease
Angiostatin, an endogenous angiogenesis inhibitor generated by the proteolytic cleavage of plasminogen, was recently reported to contribute to the development of Alzheimer’s disease (AD). However, whether there are pathological changes in angiostatin levels in individuals with AD dementia is unclear, and whether plasma angiostatin has a relationship with major AD pathological processes and cognitive impairment remains unknown. To examine plasma angiostatin levels in patients with AD dementia and investigate the associations of angiostatin with blood and cerebrospinal fluid (CSF) AD biomarkers, we conducted a cross-sectional study including 35 cognitively normal control (CN) subjects and 59 PiB-PET-positive AD dementia patients. We found that plasma angiostatin levels were decreased in AD dementia patients compared to CN subjects. Plasma angiostatin levels were negatively correlated with plasma Aβ42 and Aβ40 levels in AD dementia patients and positively correlated with CSF total tau (t-tau) levels and t-tau/Aβ42 in AD dementia patients with APOE-ε4. In addition, plasma angiostatin levels had the potential to distinguish AD from CN. These findings suggest a link between angiostatin and AD pathogenesis and imply that angiostatin might be a potential diagnostic biomarker for AD.
- 10 May 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-6
Open AccessAssociations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease
Angiostatin, an endogenous angiogenesis inhibitor generated by the proteolytic cleavage of plasminogen, was recently reported to contribute to the development of Alzheimer’s disease (AD). However, whether there are pathological changes in angiostatin levels in individuals with AD dementia is unclear, and whether plasma angiostatin has a relationship with major AD pathological processes and cognitive impairment remains unknown. To examine plasma angiostatin levels in patients with AD dementia and investigate the associations of angiostatin with blood and cerebrospinal fluid (CSF) AD biomarkers, we conducted a cross-sectional study including 35 cognitively normal control (CN) subjects and 59 PiB-PET-positive AD dementia patients. We found that plasma angiostatin levels were decreased in AD dementia patients compared to CN subjects. Plasma angiostatin levels were negatively correlated with plasma Aβ42 and Aβ40 levels in AD dementia patients and positively correlated with CSF total tau (t-tau) levels and t-tau/Aβ42 in AD dementia patients with APOE-ε4. In addition, plasma angiostatin levels had the potential to distinguish AD from CN. These findings suggest a link between angiostatin and AD pathogenesis and imply that angiostatin might be a potential diagnostic biomarker for AD.
- Open Access
- 1 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (13) , eabm5667
Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer’s disease
CD22 has been suggested to contribute to Alzheimer’s disease (AD) pathogenesis by inhibiting microglial amyloid β (Aβ) phagocytosis. Soluble CD22 (sCD22) generated by cleavage from cell membranes may be a marker of inflammation and microglial dysfunction; but alterations of sCD22 levels in AD and their correlation with AD biomarkers remain unclear. Plasma sCD22 levels were measured in cognitively normal non-AD participants and patients with preclinical AD and AD dementia from a Chinese cohort and the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Plasma sCD22 levels were elevated in patients with preclinical and dementia AD. Plasma sCD22 levels were negatively correlated with cerebrospinal fluid (CSF) Aβ42 levels and Aβ42/Aβ40, and positively correlated with CSF phosphorylated tau levels and brain Aβ burden, but negatively correlated with cognitive function. Moreover, higher plasma sCD22 levels were associated with faster cognitive decline during follow-up. These findings suggest that CD22 plays important roles in AD development, and that sCD22 is a potential biomarker for AD.
- 1 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (13) , eabm5667
Open AccessAssociations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer’s disease
CD22 has been suggested to contribute to Alzheimer’s disease (AD) pathogenesis by inhibiting microglial amyloid β (Aβ) phagocytosis. Soluble CD22 (sCD22) generated by cleavage from cell membranes may be a marker of inflammation and microglial dysfunction; but alterations of sCD22 levels in AD and their correlation with AD biomarkers remain unclear. Plasma sCD22 levels were measured in cognitively normal non-AD participants and patients with preclinical AD and AD dementia from a Chinese cohort and the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Plasma sCD22 levels were elevated in patients with preclinical and dementia AD. Plasma sCD22 levels were negatively correlated with cerebrospinal fluid (CSF) Aβ42 levels and Aβ42/Aβ40, and positively correlated with CSF phosphorylated tau levels and brain Aβ burden, but negatively correlated with cognitive function. Moreover, higher plasma sCD22 levels were associated with faster cognitive decline during follow-up. These findings suggest that CD22 plays important roles in AD development, and that sCD22 is a potential biomarker for AD.
- Open Access
- 8 December 2020
- Published by Springer Nature in Translational Psychiatry
- Vol. 10 (1) , 1-11
Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease
Deficits in the clearance of amyloid β-protein (Aβ) play a pivotal role in the pathogenesis of sporadic Alzheimer’s disease (AD). The roles of blood monocytes in the development of AD remain unclear. In this study, we sought to investigate the alterations in the Aβ phagocytosis function of peripheral monocytes during ageing and in AD patients. A total of 104 cognitively normal participants aged 22–89 years, 24 AD patients, 25 age- and sex-matched cognitively normal (CN) subjects, 15 Parkinson’s disease patients (PD), and 15 age- and sex-matched CN subjects were recruited. The Aβ uptake by blood monocytes was measured and its alteration during ageing and in AD patients were investigated. Aβ1-42uptake by monocytes decreased during ageing and further decreased in AD but not in PD patients. Aβ1-42uptake by monocytes was associated with Aβ1-42levels in the blood. Among the Aβ uptake-related receptors and enzymes, the expression of Toll-like receptor 2 (TLR2) was reduced in monocytes from AD patients. Our findings suggest that monocytes regulate the blood levels of Aβ and might be involved in the development of AD. The recovery of the Aβ uptake function by blood monocytes represents a potential therapeutic strategy for AD.
- 8 December 2020
- Published by Springer Nature in Translational Psychiatry
- Vol. 10 (1) , 1-11
Open AccessAmyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease
Deficits in the clearance of amyloid β-protein (Aβ) play a pivotal role in the pathogenesis of sporadic Alzheimer’s disease (AD). The roles of blood monocytes in the development of AD remain unclear. In this study, we sought to investigate the alterations in the Aβ phagocytosis function of peripheral monocytes during ageing and in AD patients. A total of 104 cognitively normal participants aged 22–89 years, 24 AD patients, 25 age- and sex-matched cognitively normal (CN) subjects, 15 Parkinson’s disease patients (PD), and 15 age- and sex-matched CN subjects were recruited. The Aβ uptake by blood monocytes was measured and its alteration during ageing and in AD patients were investigated. Aβ1-42uptake by monocytes decreased during ageing and further decreased in AD but not in PD patients. Aβ1-42uptake by monocytes was associated with Aβ1-42levels in the blood. Among the Aβ uptake-related receptors and enzymes, the expression of Toll-like receptor 2 (TLR2) was reduced in monocytes from AD patients. Our findings suggest that monocytes regulate the blood levels of Aβ and might be involved in the development of AD. The recovery of the Aβ uptake function by blood monocytes represents a potential therapeutic strategy for AD.